HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.

Abstract
Acquired thrombotic thrombocytopenic purpura (TTP) is an uncommon disease in adults, characterized by fever, neurological manifestations, microangiopathic hemolytic anemia, thrombocytopenia, renal dysfunction, and the presence of antibodies against the enzyme ADAMTS13. Treatment with plasmapheresis has increased the survival from 10% to more than 90%. Still, there is a subset of patients with resistant TTP who fail to respond to plasmapheresis or remain dependent on this procedure. There is mounting evidence that rituximab may play an important role in remission induction of resistant/relapsing TTP, but the extent of the remission is unknown. We present here four patients with chronic-relapsing TTP who responded favorably to rituximab. All four patients achieved prolonged remission of 23 to 82 months after the treatment. One patient relapsed 6 years afterthe initial treatment with rituximab and re-entered remission following retreatment.
AuthorsGideon Y Stein, Dorit Blickstein, Jerome Orlin, Galit Sarig, Aida Inbal
JournalThe Israel Medical Association journal : IMAJ (Isr Med Assoc J) Vol. 13 Issue 7 Pg. 398-401 (Jul 2011) ISSN: 1565-1088 [Print] Israel
PMID21838180 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Immunologic Factors
  • Rituximab
Topics
  • Adult
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antigens, CD20
  • Female
  • Follow-Up Studies
  • Humans
  • Immunologic Factors (therapeutic use)
  • Male
  • Middle Aged
  • Purpura, Thrombotic Thrombocytopenic (drug therapy)
  • Recurrence
  • Remission Induction
  • Retrospective Studies
  • Rituximab
  • Time Factors
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: